Literature DB >> 23338693

Effectiveness of antiretroviral treatment in Colombia.

Jorge Enrique Machado-Alba1, Xavier Vidal.   

Abstract

OBJECTIVE: To evaluate the effectiveness of antiretroviral therapies and factors associated with HIV/AIDS control in a population of patients treated by the Colombian Social Security Health System (SGSSS).
METHODS: This was a descriptive study of 510 HIV/AIDS patients treated with antiretroviral therapies in 19 cities in Colombia from June 1992-April 2011. Factors assessed from each patient's clinical history were: viral load, CD4 count, antiretroviral treatment regimens, prescribed daily doses of medications, length of disease evolution, duration of therapy, history of opportunistic diseases, and drug costs.
RESULTS: Patients were predominantly male (75.1% males versus 24.9% women), with a mean age of 41.0 ± 11.4 years and an average length of disease progression of 72 months. All recommended treatment regimens were prescribed at the defined daily dose. Treatment was effective in 65.3% of patients (viral load < 50 copies per mL). Non-adherence to treatment, treatment failure, the presence of anxiety or depression, and treatment in the city of Barranquilla were associated with an increased risk of uncontrolled HIV infection. The mean annual cost of drugs per patient was US$ 2,736.
CONCLUSIONS: Factors associated with uncontrolled HIV infection, especially regarding treatment adherence, must be identified to promote solutions for health care programs treating patients with HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23338693     DOI: 10.1590/s1020-49892012001100006

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  1 in total

1.  Naturally Derived Anti-HIV Polysaccharide Peptide (PSP) Triggers a Toll-Like Receptor 4-Dependent Antiviral Immune Response.

Authors:  Madeline Rodríguez-Valentín; Sheila López; Mariela Rivera; Eddy Ríos-Olivares; Luis Cubano; Nawal M Boukli
Journal:  J Immunol Res       Date:  2018-07-15       Impact factor: 4.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.